MALIGNANCY MASQUERADING AS JOINT INFECTION- A CASE REPORT

2021 ◽  
pp. 36-36
Author(s):  
Aparna C Babu ◽  
B. Manohar
Keyword(s):  
Case Report ◽  
Acute Lymphoblastic Leukemia ◽  
Childhood Leukemia ◽  
Lymphoblastic Leukemia ◽  
Joint Infection ◽  
Joint Effusion ◽  
Childhood Cancers ◽  
Prolonged Fever ◽  
Hematological Disorder ◽  
Common Malignancy

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) is the most common malignancy in children. It accounts for 25% of all childhood cancers and approximately 75% of all cases of childhood leukemia. ALL presents usually with fever, lassitude, pallor, bone pains+/- bleeds. Here, we present a case of a child presenting with prolonged fever and swelling and pain in joints. Child was initially diagnosed as one hematological disorder and presented with joint effusion within a week.

scholarly journals Acute lymphoblastic leukemia presenting as cholestatic jaundice in a 7-year-old boy

2019 ◽  
Vol 7 ◽  
pp. 2050313X1987531
Author(s):  
Jessica Ford ◽  
Shane Rainey ◽  
Keith Hanson ◽  
Harleena Kendhari
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Marked Improvement ◽  
Childhood Leukemia ◽  
Pediatric Population ◽  
Lymphoblastic Leukemia ◽  
Clinical Manifestations ◽  
Diagnostic Challenge ◽  
Elevated Transaminase ◽  
Motor Tics ◽  
Common Malignancy

This is a case of a 7-year-old boy with acute lymphoblastic leukemia presenting with cholestasis and elevated transaminase levels. Acute lymphoblastic leukemia is the most common malignancy in children and can have variable presenting clinical manifestations. However, cholestasis is less commonly encountered in the pediatric population and can be a diagnostic challenge. We present a case of a 7-year-old boy discovered to have elevated transaminase levels while undergoing an evaluation for motor tics, which subsequently progressed to cholestasis and acute liver failure secondary to acute lymphoblastic leukemia. He demonstrated marked improvement after induction therapy and is in clinical remission. Clinicians should be ever mindful of the potentially unique presentations of childhood leukemia.

Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease

2018 ◽  
Vol 25 (8) ◽  
pp. 2027-2030 ◽  
Author(s):  
Jason Chen ◽  
Dat Ngo ◽  
Joseph Rosenthal
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Central Nervous System Involvement ◽  
Altered Mental Status ◽  
Intrathecal Chemotherapy ◽  
Speech Impairment ◽  
Central Nervous System Toxicity

A 26-year-old male with a history of pre-B cell acute lymphoblastic leukemia and seizures presented with second relapse of acute lymphoblastic leukemia and central nervous system involvement, 19 years after the initial diagnosis. Over the next two months, the patient received six doses of triple intrathecal chemotherapy (cytarabine, methotrexate, and hydrocortisone), three concurrently with continuous blinatumomab in the second month. Approximately 12 days after blinatumomab initiation, he developed central nervous system toxicity manifesting as speech impairment, altered mental status, incontinence, and diffuse weakness. Blinatumomab was discontinued, and he was started on dexamethasone. Within the next couple of months, his neurologic status recovered, and he was able to perform all of his baseline activities without limitation. Unfortunately, the patient eventually expired after further relapse approximately one year later. To our knowledge, this is the first published case report of severe neurotoxicity in a patient who was given blinatumomab concurrently with intrathecal chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document